Olema Pharmaceuticals (NASDAQ:OLMA – Get Rating) had its target price decreased by Credit Suisse Group from $12.00 to $11.00 in a research report report published on Friday morning, Benzinga reports. Credit Suisse Group currently has an outperform rating on the stock.
Separately, HC Wainwright increased their price target on Olema Pharmaceuticals from $12.00 to $15.00 and gave the stock a buy rating in a research report on Friday.
Olema Pharmaceuticals Trading Up 1.0 %
Shares of OLMA stock opened at $3.93 on Friday. The company has a market capitalization of $159.68 million, a P/E ratio of -1.50 and a beta of 2.36. The business’s 50 day moving average is $4.22 and its two-hundred day moving average is $3.49. Olema Pharmaceuticals has a 12-month low of $2.00 and a 12-month high of $6.08.
Hedge Funds Weigh In On Olema Pharmaceuticals
A number of hedge funds have recently made changes to their positions in OLMA. Kynam Capital Management LP raised its holdings in shares of Olema Pharmaceuticals by 461.6% during the third quarter. Kynam Capital Management LP now owns 1,399,633 shares of the company’s stock valued at $3,863,000 after acquiring an additional 1,150,404 shares during the last quarter. Sectoral Asset Management Inc. raised its holdings in shares of Olema Pharmaceuticals by 63.3% during the fourth quarter. Sectoral Asset Management Inc. now owns 1,441,805 shares of the company’s stock valued at $3,532,000 after acquiring an additional 558,749 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Olema Pharmaceuticals by 653.2% during the second quarter. Millennium Management LLC now owns 643,344 shares of the company’s stock valued at $2,618,000 after acquiring an additional 557,927 shares during the last quarter. Laurion Capital Management LP acquired a new position in shares of Olema Pharmaceuticals during the second quarter valued at approximately $2,016,000. Finally, Deutsche Bank AG raised its holdings in shares of Olema Pharmaceuticals by 709.2% during the second quarter. Deutsche Bank AG now owns 456,666 shares of the company’s stock valued at $1,859,000 after acquiring an additional 400,229 shares during the last quarter. Institutional investors and hedge funds own 82.41% of the company’s stock.
Olema Pharmaceuticals Company Profile
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
- Get a free copy of the StockNews.com research report on Olema Pharmaceuticals (OLMA)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.